Rakuten Medical - To conquer cancer.

Rakuten Medical Logo

Partnering

About Partnering

We are interested in multiple alliance structures that can build upon and expand on the Alluminox™ platform to advance treatment options for patients with cancer.

In-Licensing
 

Therapies or devices that can be incorporated into our Alluminox™ platform and tumor microenvironment.

Clinical
collaborations

Therapies that can be developed in combination with our lead drug, ASP-1929.

Partnerships
 

Companies that can assist in the clinical development and commercialization of our lead product, ASP-1929, in specific geographic territories.

Academic
Institutions

Centers of excellence that can participate in the clinical development and enrollment of our clinical trials for investigational products developed on the Alluminox™ platform.

Presentations

Links to past events and presentations hosted by Rakuten Medical.

10JAN23 – 41st Annual J.P. Morgan Healthcare Conference ( Presentation / Audio Recording)
10JAN22 - 40th Annual J.P. Morgan Healthcare Conference ( Webcast /Presentation ) ​
11JAN21 - 39th Annual J.P. Morgan Healthcare Conference
19JAN21 - VP Global Corporate and Business Development (Abhijit Bhatia) - Price of Business Interview

DISCLAIMER: Outside of Japan, ASP-1929 photoimmunotherapy is investigational

Related Content

People
×
Innovation
×
Action
×
A Note from Our Chairman

In 2012, my father was diagnosed with pancreatic cancer. I was ready to do anything for him to be cured. With that sole purpose, I read many scientific papers from all over the world, and I met and talked with numerous experts in the field. How could I cure my father’s cancer? I searched every single possibility available.

That is when I found out about photoimmunotherapy that was only at an early stage of research. Although I had many doubts about this completely new approach, desperate for a miracle, I immediately went to meet the researcher.

Everyone was still doubtful at that stage. But the more I heard about this research, the more it made sense. 

I instinctively thought, “This is it.” It was the same feeling I got as when I grasped that the internet would change the world forever. Somehow, wishing to save my father, I immediately made up my mind to support the research personally to speed it up.

Unfortunately, we didn’t make it in time to save my father. But I decided to continue my support. My father who was as an economist always said, “One important mission of corporations is to contribute to humanity.”

Left behind, I resolved to provide this latest treatment to as many people as possible. It will surely be a path fraught with difficulties. But right at this moment there are many who are suffering from cancer, many who wish to save the lives of their loved ones, and I know exactly how they feel.

To provide this treatment as soon as possible, to bring this treatment to as many people as possible, I will not fail to support this research from now on.

Chairman, Rakuten Medical, Inc.

Hiroshi Mikitani

×